Evidence map›Paper›PMID 35108561›Full record

ArticleToxicology and applied pharmacology2022

Effect of dexamethasone treatment at variable therapeutic windows in reversing nitrogen mustard-induced corneal injuries in rabbit ocular in vivo model.

Dinesh G Goswami, Neha Mishra, Rama Kant, Chapla Agarwal, David A Ammar, J Mark Petrash, Neera Tewari-Singh, Rajesh Agarwal

Open access · greenAbstract read
In one paragraph

Article in Toxicology and applied pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
4.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Dinesh G GoswamiDepartment of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
Neha MishraDepartment of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
Rama KantDepartment of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
Chapla AgarwalDepartment of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
David A AmmarDepartment of Ophthalmology, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
J Mark PetrashDepartment of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, United States; Department of Ophthalmology, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
Neera Tewari-SinghDepartment of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
Rajesh AgarwalDepartment of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, United States. Electronic address: rajesh.agarwal@cuanschutz.edu.
University of Colorado Anschutz Medical Campus · US

Funding

Effective Therapies for Ocular Injuries by Vesicating AgentsU01EY023143 · NEI · UNIVERSITY OF COLORADO DENVER · PI AGARWAL, RAJESH · 2012 to 2016
$3.9M
Dexamethasone as an Effective Therapy for Ocular Injuries by Vesicating Agents.U01EY030405 · NEI · UNIVERSITY OF COLORADO DENVER · PI AGARWAL, RAJESH · 2020 to 2023
$2.9M
NEI NIH HHS U01 EY023143NEI NIH HHS U01 EY030405
6 · The paper itself

Abstract

Nitrogen mustard (NM) is an analogue of the potent vesicating agent sulfur mustard, with well-established ocular injury models in rabbit eyes to study vesicant-induced ocular toxicity. The effects of NM-exposure to eyes may include irritation, redness, inflammation, fibrosis, epithelial degradation, blurred vision, partial/complete blindness, which may be temporary or permanent, depending on the route, duration, and dosage of exposure. Effective countermeasures against vesicant exposure are presently not available and are warranted in case of any terrorist activity or accidental leakage from stockpiles. Herein, our focus was to evaluate whether dexamethasone (DEX), an FDA approved potent corticosteroid with documented anti-inflammatory activities, could be an effective treatment modality. Accordingly, utilizing NM-induced corneal injuries in rabbit ocular in vivo model, we examined and compared the efficacy of DEX treatments when administration was started at early (2 h), intermediate (4 h), and late (6 h) therapeutic windows of intervention after NM-exposure and administered every 8 h thereafter. The effects of NM-exposure and DEX treatments were evaluated on clinical (corneal opacity, ulceration, and neovascularization), biological (epithelial thickness, epithelial-stromal separation, blood vessels density, and inflammatory cell and keratocyte counts) and molecular (COX-2 and VEGF expression) parameters, at day 1, 3, 7 and 14. Results indicated that DEX treatment markedly and effectively reversed the NM-induced injury markers in rabbit corneas. Early administration of DEX at 2 h was found to be most effective in reversing NM-induced corneal injuries, followed by DEX 4 h and DEX 6 h administration initiation, indicating that DEX has best efficacy at the early therapeutic window in our study model.

Indexed as

AnimalsAnti-Inflammatory AgentsBiomarkersCorneal InjuriesDexamethasoneIrritantsMaleMechlorethamineRabbitsAnti-Inflammatory AgentsBiomarkersDexamethasoneIrritantsMechlorethamineCorneal inflammationCorneal injuryCorneal neovascularizationDexamethasoneEpithelial degradationNitrogen mustardVesicant

Identifiers

PMID35108561
PMCPMC8849585
OpenAlexW4210252426

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.